Vitamin E and Alzheimer’s disease: what do we know so far?
Declan Browne, Bernadette McGuinness, Jayne V Woodside, Gareth J McKayCentre for Public Health, Queen’s University Belfast, Belfast, UKAbstract: Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various bio...
Saved in:
Main Authors: | Browne D, McGuinness B, Woodside JV, McKay GJ |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/b9d2e66d8f634e0ea0e5e80bb9ca25fb |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacology and Pharmacokinetics of Vitamin E: Nanoformulations to Enhance Bioavailability
by: Mohd Zaffarin AS, et al.
Published: (2020) -
Cholesterol and vitamin E determination in broiler chickens fed cañóla oil
by: Gallardo,MA, et al.
Published: (2015) -
TAVI in nonagenarians, what do we know so far?
by: Pablo Díez-Villanueva, et al.
Published: (2021) -
Equine degenerative myeloencephalopathy: prevalence, impact, and management
by: Burns EN, et al.
Published: (2018) -
Identifying High-Risk NASH Patients: What We Know so Far
by: Schulz M, et al.
Published: (2020)